DBS Chola MF has announced the launch of DBS Chola Fixed Maturity Plan Series 11 (13 months) in the Indian market.
The fund is a close ended income scheme with an objective to generate regular returns and capital appreciation by investing in debt (including securitized debt), Government and Money Market securities maturing in line with time profile of the respective plans.
The Benchmark for the fund will be Crisil Short Term Fund Index.
The minimum investment amount will be Rs 10,000 and in multiples of Re. 1 thereafter. For the institutional plan, the minimum application amount is Rs 1 crore and in multiples of Re. 1 thereafter.
Mumbai-based Unichem Laboratories has finally received nod from US Food & Drug Administration (USFDA) for Hydrochlorothiazide tablets in the strengths of 25 mg and 50 mg.
Pharmaceutical major Aurobindo Pharma has informed that it has received tentative approval from the US Food and Drug Administration (USFDA) to market Efavirenz tablets, in the strength of 600 mg.
